Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Craddock

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
Bone Marrow Transplantation|November 26, 2008
Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AMLR K Malladi, A J Peniket, T J Littlewood, et al.
Bone Marrow Transplantation|October 7, 2014
Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation studyE Nikolousis, S Nagra, R Pearce, et al.
Bone Marrow Transplantation|January 15, 2014
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationF Baron, M Labopin, D Blaise, et al.
Leukemia|November 27, 2014
Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemiaC Bradbury, A E Houlton, S Akiki, et al.
Leukemia Research|February 12, 2013
Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplantE Nikolousis, S Robinson, S Nagra, et al.
Leukemia|February 23, 2011
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemiaC Craddock, M Labopin, S Pillai, et al.
Bone Marrow Transplantation|October 27, 2015
Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working PartiesO Penack, G Tridello, J Hoek, et al.
British Journal of Cancer|October 9, 1998
High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levelsE J Kanfer, D McGuigan, D Samson, et al.
Bone Marrow Transplantation|February 11, 2014
Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphomaI Avivi, C Canals, J-P Vernant, et al.
Cochlear Implants International|April 28, 2023
Cochlear implant services for children, young people and adults. Quality standardH E Cullington, D Jiang, S J Broomfield, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Bone Marrow Transplantation|November 26, 2008
Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AMLR K Malladi, A J Peniket, T J Littlewood, et al.
Bone Marrow Transplantation|October 7, 2014
Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation studyE Nikolousis, S Nagra, R Pearce, et al.
Bone Marrow Transplantation|January 15, 2014
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationF Baron, M Labopin, D Blaise, et al.
Leukemia|November 27, 2014
Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemiaC Bradbury, A E Houlton, S Akiki, et al.
Leukemia Research|February 12, 2013
Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplantE Nikolousis, S Robinson, S Nagra, et al.
Leukemia|February 23, 2011
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemiaC Craddock, M Labopin, S Pillai, et al.
Bone Marrow Transplantation|October 27, 2015
Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working PartiesO Penack, G Tridello, J Hoek, et al.
British Journal of Cancer|October 9, 1998
High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levelsE J Kanfer, D McGuigan, D Samson, et al.
Bone Marrow Transplantation|February 11, 2014
Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphomaI Avivi, C Canals, J-P Vernant, et al.
Cochlear Implants International|April 28, 2023
Cochlear implant services for children, young people and adults. Quality standardH E Cullington, D Jiang, S J Broomfield, et al.
Pageof 13